Dr. Gojo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 N Wolfe St
Baltimore, MD 21287Phone+1 410-955-9441Fax+1 410-328-6896
Education & Training
- University of MarylandFellowship, Hematology and Medical Oncology, 1998 - 2001
- Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalResidency, Internal Medicine, 1995 - 1998
- University of Zagreb Faculty of MedicineClass of 1992
Certifications & Licensure
- MD State Medical License 2001 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes Start of enrollment: 2005 Dec 01
- Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia Start of enrollment: 2010 Apr 01
- Veliparib and Temozolomide in Treating Patients With Acute Leukemia Start of enrollment: 2010 May 21
- Join now to see all
Publications & Presentations
PubMed
- 77 citationsRandomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute my...Joshua F. Zeidner, Matthew C. Foster, Amanda L. Blackford, Mark R. Litzow, Lawrence E. Morris
Haematologica. 2015-09-01 - 94 citationsMyeloid growth factors, version 2.2017Jeffrey Crawford, Pamela S. Becker, James O. Armitage, Douglas W. Blayney, Julio C. Chavez
Journal of the National Comprehensive Cancer Network. 2017-12-01 - 79 citationsTargeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemiasLisa A. Tobin, Carine Robert, Aaron P. Rapoport, Ivana Gojo, Maria R. Baer
Oncogene. 2013-04-04
Journal Articles
- Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research
Abstracts/Posters
- Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)Clinicall...Ivana Gojo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume LeukapheresisIvana Gojo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or M...Ivana Gojo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Authored Content
- Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018
Other Languages
- Croatian
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/ivana-gojo
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: